HZNP News and Press, Horizon Therapeutics Public Limited Company From 10/06/22

-- Dave Thomas Foundation for Adoption Also Names Horizon a Top 100 Adoption-Friendly Workplace -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named to Newsweek’s 2022 Top 100 Most Loved Workplaces ® list for prioritizing respect,...

Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it will release its third-quarter 2022 financial results on Wednesday, Nov. 2, 2022. Following the announcement, Horizon’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financ...

Summary My portfolio, built specifically for my retirement ~20+ years from now, had a crushing September, along with the rest of the market, in spite of amazing Petrobras dividends. Making monthly contributions, even though they seem small at the time, makes all the difference in ...

-- Oral presentation at AAO 2022 suggests IGF-1 and its related pathways are extensively upregulated throughout all stages of TED -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of new data defining molecular patterns in TED and further implic...

-- Topline results expected in second quarter of 2023 -- Horizon Therapeutics plc (Nasdaq: HZNP) announced that it has completed enrollment of its Phase 4 clinical trial ( NCT04583735 ) evaluating TEPEZZA for the treatment of Thyroid Eye Disease (TED) in patients with a ...

Summary Baker Brothers’ 13F portfolio value increased from $17.40B to $17.63B this quarter. Global Blood Therapeutics, Horizon Therapeutics, and Kymera Therapeutics were increased during the quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, a...

-- Company Also Funds and Mentors Scholars at Howard University, Harris-Stowe State University and Charles Drew University of Medicine and Science -- Horizon Therapeutics plc (Nasdaq: HZNP) today expanded its commitment to education equity, science, technology, engineering, arts...

Horizon Therapeutics ( NASDAQ: HZNP ) said it paid a milestone payment to HemoShear Therapeutics for advancing potential product candidates against a second target to treat gout under their collaboration. "In three years, HemoShear has identified tw...

--Organization Will Utilize GPS and Web Services to Build a Patient-Driven Platform for the Epidermolysis Bullosa (EB) Community and Accelerate a Cure -- Horizon Therapeutics plc (Nasdaq: HZNP), in collaboration with MIT Solve, a marketplace for social impact innovation, is ...

– Meeting plenary session to feature 12-Month data from MIRROR randomized controlled trial of KRYSTEXXA ® (pegloticase) injection with methotrexate – Horizon Therapeutics plc (Nasdaq: HZNP) today announced plans for a series of data presentations o...